Compare OPRA & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPRA | GHRS |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | Norway | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2018 | 2021 |
| Metric | OPRA | GHRS |
|---|---|---|
| Price | $11.75 | $13.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $23.50 | ★ $32.90 |
| AVG Volume (30 Days) | ★ 829.2K | 286.8K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $583,449,000.00 | N/A |
| Revenue This Year | $27.78 | N/A |
| Revenue Next Year | $14.63 | N/A |
| P/E Ratio | $13.12 | ★ N/A |
| Revenue Growth | ★ 30.29 | N/A |
| 52 Week Low | $11.71 | $7.98 |
| 52 Week High | $22.50 | $19.51 |
| Indicator | OPRA | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 38.43 |
| Support Level | $12.41 | $15.50 |
| Resistance Level | $14.87 | $16.48 |
| Average True Range (ATR) | 0.69 | 0.94 |
| MACD | -0.15 | -0.30 |
| Stochastic Oscillator | 1.58 | 1.35 |
Opera Ltd is a world-wide internet brand with a large, engaged, and growing base. It offers users products and services that include a variety of PC and mobile browsers, Opera Gaming portals and development tools, Opera News content recommendation products, and a number of e-commerce products and services. Its browser's features include tabbed browsing, data savings, PC/mobile sync, and numerous features focused on privacy and security, including ad blocking and a built-in VPN. Its browser products include Opera Mini, Opera Browser for Android and iOS, Opera for Computers, Opera GX and Opera GX Mobile, separate browsers tailored for gamers. Geographically, the company generates maximum revenue from the United States, followed by Singapore, Nigeria, Russia, and other locations.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.